drugset / Trial / NCT07294872
A Study of TIL in Advanced Solid Tumors (CZ)
Phase 1
Not yet recruiting
30 enrolled
Shanghai Juncell Therapeutics
Sichuan Cancer Hospital and Research Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Timeline
- Start
- 2026-05-08
- Primary completion
- 2026-09-20
- Completion
- 2029-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC101 TIL | Cell therapy | — | Intravenous |